Form 4: Lilly Endowment Sells LLY Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 2,629 shares of common stock for approximately $1,085.17 per share.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), reported the disposition of 2,629 shares of common stock.
• The transaction occurred on December 24, 2025.
• The shares were sold at a weighted average price of $1,085.173 per share, with individual transaction prices ranging from $1,085.00 to $1,085.53.
• Following this transaction, Lilly Endowment Inc. directly beneficially owns 92,194,109 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider sale by a 10% owner. The number of shares sold is a small fraction of the total beneficial ownership, suggesting it is a standard portfolio adjustment rather than a significant change in sentiment.

Negatives

• A 10% owner, Lilly Endowment Inc., sold 2,629 shares of common stock. While a small percentage of their total holding, insider sales can sometimes be viewed with caution by investors.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., engaged in a transaction involving the issuer's common stock. This constitutes a related party transaction due to the significant ownership stake.

Stakeholder Impact

• Shareholders: Minimal direct impact due to the relatively small number of shares sold compared to the total outstanding shares and Lilly Endowment's overall holding. Could be perceived as a minor negative signal by some, but likely offset by the routine nature of such disclosures.
• Company (Eli Lilly & Co.): No direct operational or financial impact from this transaction.

Key Dates

Keywords

Eli Lilly, LLY, Lilly Endowment Inc., Insider Sale, Form 4, Beneficial Ownership, Stock Transaction, Pharmaceuticals